: D933GC00002: A Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolization Using Yttrium-90 Glass Microspheres (TheraSphere™) in Unresectable Hepatocellular Carcinoma
This study is currently enrolling.
AstraZeneca is doing this study to learn more about durvalumab and bevacizumab given together after the TARE Y90 procedure in participants with HCC, and also to better understand HCC and associated health problems. Patients wit ...